Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCX NASDAQ:MGRM NASDAQ:SGHT NASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.54-1.6%$2.96$0.17▼$1.27$53.09M0.514.65 million shs7,876 shsMGRMMonogram Orthopaedics$5.80+0.3%$4.85$1.92▼$6.02$235.67M0.69128,689 shs43,863 shsSGHTSight Sciences$4.06+0.5%$3.85$2.03▼$7.03$212.61M2.46121,966 shs59,857 shsSTIMNeuronetics$3.33-3.2%$3.76$0.52▼$5.92$220.20M1.281.67 million shs1.47 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell0.00%-2.59%-13.02%-23.04%+298.07%MGRMMonogram Orthopaedics0.00%+6.42%+7.61%+140.66%+110.91%SGHTSight Sciences0.00%-4.02%+24.16%+4.37%-40.03%STIMNeuronetics0.00%-2.06%-24.66%-12.60%+277.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AMGRMMonogram Orthopaedics1.6023 of 5 stars1.85.00.00.02.31.70.6SGHTSight Sciences2.041 of 5 stars2.23.00.00.02.63.30.6STIMNeuronetics1.8516 of 5 stars3.51.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AMGRMMonogram Orthopaedics 3.50Strong Buy$5.40-6.90% DownsideSGHTSight Sciences 2.43Hold$4.428.78% UpsideSTIMNeuronetics 3.00Buy$7.00110.21% UpsideCurrent Analyst Ratings BreakdownLatest CTCX, STIM, MGRM, and SGHT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/21/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.60 ➝ $4.508/8/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$3.00 ➝ $5.008/6/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.007/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,616.75N/AN/A$1.07 per share2.37MGRMMonogram Orthopaedics$370K636.90N/AN/A$0.42 per share13.81SGHTSight Sciences$79.87M2.66N/AN/A$1.72 per share2.36STIMNeuronetics$74.89M2.94N/AN/A$0.57 per share5.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AMGRMMonogram Orthopaedics-$16.33M-$0.50N/AN/AN/AN/A-126.82%-96.87%11/13/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.96N/AN/AN/A-64.23%-59.38%-36.43%11/6/2025 (Estimated)STIMNeuronetics-$43.71M-$1.13N/AN/AN/A-43.47%-156.36%-35.69%11/11/2025 (Estimated)Latest CTCX, STIM, MGRM, and SGHT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025MGRMMonogram Orthopaedics-$0.11-$0.16-$0.05-$0.16N/AN/A8/7/2025Q2 2025SGHTSight Sciences-$0.25-$0.23+$0.02-$0.23$18.18 million$19.56 million8/5/2025Q2 2025STIMNeuronetics-$0.08-$0.15-$0.07-$0.15$36.80 million$38.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29MGRMMonogram OrthopaedicsN/A2.162.16SGHTSight Sciences0.5710.019.49STIMNeuronetics1.762.021.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%MGRMMonogram Orthopaedics0.45%SGHTSight Sciences55.51%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%MGRMMonogram Orthopaedics28.10%SGHTSight Sciences28.90%STIMNeuronetics9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableMGRMMonogram Orthopaedics2840.63 million29.21 millionNot OptionableSGHTSight Sciences21052.37 million37.23 millionOptionableSTIMNeuronetics18066.12 million59.65 millionOptionableCTCX, STIM, MGRM, and SGHT HeadlinesRecent News About These CompaniesHighTower Advisors LLC Reduces Holdings in Neuronetics, Inc. $STIMSeptember 1 at 3:41 AM | marketbeat.com104,597 Shares in Neuronetics, Inc. (NASDAQ:STIM) Purchased by Informed Momentum Co LLCAugust 15, 2025 | marketbeat.comCitizens Financial Group Inc. RI Invests $305,000 in Neuronetics, Inc. (NASDAQ:STIM)August 10, 2025 | marketbeat.comCanaccord Genuity Group Has Lowered Expectations for Neuronetics (NASDAQ:STIM) Stock PriceAugust 7, 2025 | marketbeat.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 6, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | msn.comNeuronetics (NASDAQ:STIM) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPSAugust 6, 2025 | marketbeat.comNeuronetics, Inc. (STIM) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comNeuronetics Reports Second Quarter 2025 Financial and Operating ResultsAugust 5, 2025 | manilatimes.netMWhat To Expect From Neuronetics Inc (STIM) Q2 2025 EarningsAugust 5, 2025 | finance.yahoo.comNeuronetics (STIM) Reports Q2 Loss, Tops Revenue EstimatesAugust 5, 2025 | zacks.comNeuronetics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 4, 2025 | globenewswire.comNeuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMSAugust 2, 2025 | msn.comNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsJuly 30, 2025 | globenewswire.comNeuronetics taps local industry veteran as new CFOJuly 15, 2025 | bizjournals.comNeuronetics Names Pfanstiel as CFO to Succeed FurlongJuly 15, 2025 | marketwatch.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | finance.yahoo.comNeuronetics names Steven Pfanstiel chief financial officerJuly 15, 2025 | massdevice.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | globenewswire.comNeuronetics Showcases NeuroStar TMS Data at Clinical TMS MeetingJuly 10, 2025 | msn.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?By Ryan Hasson | August 9, 2025CTCX, STIM, MGRM, and SGHT Company DescriptionsCarmell NASDAQ:CTCX$2.54 -0.04 (-1.56%) As of 08/29/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Monogram Orthopaedics NASDAQ:MGRM$5.80 +0.02 (+0.35%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.80 0.00 (-0.09%) As of 08/29/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.Sight Sciences NASDAQ:SGHT$4.06 +0.02 (+0.50%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.06 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Neuronetics NASDAQ:STIM$3.33 -0.11 (-3.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.33 0.00 (0.00%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
